JP2019529408A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529408A5
JP2019529408A5 JP2019514208A JP2019514208A JP2019529408A5 JP 2019529408 A5 JP2019529408 A5 JP 2019529408A5 JP 2019514208 A JP2019514208 A JP 2019514208A JP 2019514208 A JP2019514208 A JP 2019514208A JP 2019529408 A5 JP2019529408 A5 JP 2019529408A5
Authority
JP
Japan
Prior art keywords
component
weight
preliminary preparation
ethanol
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019514208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529408A (ja
JP7527785B2 (ja
Filing date
Publication date
Priority claimed from GBGB1615754.7A external-priority patent/GB201615754D0/en
Priority claimed from GBGB1621277.1A external-priority patent/GB201621277D0/en
Application filed filed Critical
Priority claimed from PCT/EP2017/073359 external-priority patent/WO2018050864A1/en
Publication of JP2019529408A publication Critical patent/JP2019529408A/ja
Publication of JP2019529408A5 publication Critical patent/JP2019529408A5/ja
Application granted granted Critical
Publication of JP7527785B2 publication Critical patent/JP7527785B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019514208A 2016-09-15 2017-09-15 プロスタサイクリン類似体製剤 Active JP7527785B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1615754.7A GB201615754D0 (en) 2016-09-15 2016-09-15 Formulations
GB1615754.7 2016-09-15
GB1621277.1 2016-12-14
GBGB1621277.1A GB201621277D0 (en) 2016-12-14 2016-12-14 Formulations
PCT/EP2017/073359 WO2018050864A1 (en) 2016-09-15 2017-09-15 Prostacyclin analogue formulations

Publications (3)

Publication Number Publication Date
JP2019529408A JP2019529408A (ja) 2019-10-17
JP2019529408A5 true JP2019529408A5 (OSRAM) 2020-10-22
JP7527785B2 JP7527785B2 (ja) 2024-08-05

Family

ID=59887281

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019514208A Active JP7527785B2 (ja) 2016-09-15 2017-09-15 プロスタサイクリン類似体製剤

Country Status (17)

Country Link
US (3) US11369617B2 (OSRAM)
EP (1) EP3512495B1 (OSRAM)
JP (1) JP7527785B2 (OSRAM)
KR (1) KR20190083645A (OSRAM)
CN (1) CN109715138B (OSRAM)
AU (1) AU2017328630B2 (OSRAM)
CA (1) CA3036307A1 (OSRAM)
DK (1) DK3512495T3 (OSRAM)
ES (1) ES2933175T3 (OSRAM)
IL (1) IL265270B (OSRAM)
LT (1) LT3512495T (OSRAM)
MX (1) MX390136B (OSRAM)
PL (1) PL3512495T3 (OSRAM)
PT (1) PT3512495T (OSRAM)
RU (1) RU2757903C2 (OSRAM)
SI (1) SI3512495T1 (OSRAM)
WO (1) WO2018050864A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109150387B (zh) 2017-06-16 2023-04-28 华为技术有限公司 发送参考信号的方法、接收参考信号的方法和通信装置
WO2020240018A1 (en) 2019-05-29 2020-12-03 Camurus Ab Administration device & regime
US20230248801A1 (en) * 2020-06-30 2023-08-10 Chong Kun Dang Pharmaceutical Corp. INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE
JP2023543037A (ja) * 2020-09-25 2023-10-12 アルゴリズム サイエンシズ,インコーポレイテッド 血管拡張剤送達のための組成物及び方法
WO2024107096A1 (en) * 2022-11-14 2024-05-23 Camurus Ab Treprostinil formulations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4125255A1 (de) 1991-07-31 1993-02-04 Knoll Ag Prostaglandin e (pfeil abwaerts)1(pfeil abwaerts)-formulierung
DE69425750T2 (de) 1993-07-28 2001-04-26 Pharmaderm Laboratories Ltd., Saskatoon Zweiphasige multilamellare lipidvesikel
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
CN101265226B (zh) * 2003-05-22 2013-04-24 联合治疗公司 化合物和释放前列环素类似物的方法
PL1768650T3 (pl) * 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
US20060147520A1 (en) * 2004-07-26 2006-07-06 Curtis Ruegg Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
WO2006075125A1 (en) 2005-01-14 2006-07-20 Camurus Ab GnRH ANALOGUE FORMULATIONS
CA2609810C (en) 2005-06-06 2012-05-22 Camurus Ab Glp-1 analogue formulations
EP2714004B1 (en) 2011-05-25 2024-05-15 Camurus AB Controlled release peptide formulations
BR112014003240A2 (pt) 2011-08-12 2017-03-01 Ascendis Pharma As composição de prostaciclina com liberação sustentada
JP6092867B2 (ja) * 2011-08-12 2017-03-08 アセンディス ファーマ エー/エス 担体連結しているトレプロスチニルプロドラッグ
WO2013038460A1 (ja) 2011-09-16 2013-03-21 株式会社日立製作所 画像表示システム及びその方法
DK2787974T3 (en) * 2011-12-05 2017-07-17 Camurus Ab Robust PEPTID FORMULATIONS WITH CONTROLLED RELEASE
AU2013294915C1 (en) * 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
JP6357481B2 (ja) 2012-11-30 2018-07-11 インスメッド, インコーポレイテッド プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法
KR101586790B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
WO2015138423A1 (en) 2014-03-11 2015-09-17 Insmed Incorporated Prostacylin compositions and methods for using the same
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2019529408A5 (OSRAM)
JP7250689B2 (ja) 活性化合物のための局所送達系
JP2013500239A5 (OSRAM)
ES2352222T3 (es) Preparación farmacéutica y/o cosmética que contiene un organoxilosano y un fosfolípido.
ES2145115T4 (es) Composiciones inyectables a base de derivados de taxanos.
KR102098980B1 (ko) 오피오이드 제형
JP2015531344A5 (OSRAM)
ES2682075T3 (es) Formulaciones para el tratamiento de dolor de tejido profundo
ES2958524T3 (es) Isomiosmina para uso en el tratamiento de enfermedades autoinmunes
BR112013019732B1 (pt) Composição farmacêutica e seu uso no tratamento de doenças cardiovasculares
BR112015015870B1 (pt) Uso de uma composição farmacêutica
CN109010255B (zh) 阿片样物质制剂
KR20120129864A (ko) 소포성 제형
ES2823589T3 (es) Formulaciones farmacéuticas para la administración subcutánea de furosemida
BR112017013471A2 (pt) Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit.
BR112020023741A2 (pt) filme, métodos de tratamento de condições em pacientes humanos e de fabricação de filmes e uso de filme
CN109715138B (zh) 前列环素类似物制剂
BR112012015016B8 (pt) formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação
Buys et al. Lipid emulsion therapy: non-nutritive uses of lipid emulsions in anaesthesia and intensive care
BR112015018144A8 (pt) composição de emulsão água/óleo farmacêutica estável com gotículas de óleo manométricas, método para fazer a mesma e alta dose única de clopidogrel usada para tratar um paciente
JP5509090B2 (ja) ピラゾロン誘導体のエマルジョン製剤
JP6374558B2 (ja) 皮膚科障害または皮膚科疾患を処置するための新規製剤および方法
WO2012109151A1 (en) Permeation enhancers with liposomes for topical formulations
KR20150004798A (ko) 소포성 제형
CN103054799A (zh) 一种盐酸胺碘酮注射乳剂及其制备方法